Acasti Pharma (NASDAQ:ACST) Posts Quarterly Earnings Results, Beats Expectations By $0.30 EPS

Acasti Pharma (NASDAQ:ACST) issued its earnings results on Friday. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.30, Yahoo Finance reports.

Acasti Pharma Stock Up 4.8 %

NASDAQ ACST opened at $3.30 on Monday. The company has a fifty day moving average of $2.94 and a two-hundred day moving average of $2.91. Acasti Pharma has a 52 week low of $1.72 and a 52 week high of $3.84.

Acasti Pharma Company Profile

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.